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Editorial
Hyperphosphatemia is an exceedingly common compli-
cation in patients with end-stage renal disease (ESRD).
Recent retrospective analysis of data from the US Re-
nal Data System Case-Mix Adequacy Study and the
Dialysis Morbidity and Mortality Wave II Study showed
that of the total 6,407 prevalent long-term hemodialysis
patients, 70% had serum phosphorus levels greater than
1.6 mmol/L. Nearly half of these patients had serum
phosphorus levels greater than 1.9 mmol/L, and 39%
had serum phosphorus levels greater than 2.1 mmol/L,
indicating a high prevalence of hyperphosphatemia
in the ESRD population [1]. Moreover, these studies
showed an important association between serum phos-
phorus level and mortality in hemodialysis patients: for
every 0.3 mmol/L increase in serum phosphorus levels,
there was a 6% increase in mortality risk [1]. Patients
with serum phosphorus levels of 2.1–2.5 mmol/L had
an 18% greater mortality risk, whereas those with levels
of 2.6–5.5 mmol/L had a 39% greater mortality risk
than those with levels of 1.5–1.8 mmol/L. Adjusting
for other potential confounders (including comorbid
conditions, nutritional status, and delivered dose of
dialysis) did not lower the mortality risk for patients
with serum phosphorus levels greater than 2.1 mmol/L
[1].
The prevalence of hyperphosphatemia is high-
ly variable across different countries. Although the
traditional Chinese diet is rich in vegetables and has a
low protein content, hyperphosphatemia is a frequent
complication in Chinese peritoneal dialysis (PD)
patients. In a cross-sectional study of 252 prevalent
Chinese PD patients in Hong Kong, the average serum
phosphorus level was 1.68 ± 0.48 mmol/L [2]. More
importantly, serum phosphorus levels were greater
than 1.8 mmol/L in 44% of anuric patients versus 29%
of patients with residual renal function. In this study,
multiple regression analysis showed that residual
glomerular filtration, despite an average of less than
2 mL/min/1.73m2, was independently associated with
phosphorus control in PD patients [2]. It could be
argued that Hong Kong Chinese consume a relatively
westernized diet with high phosphorus content.
In this issue of the Hong Kong Journal of Nephro-
logy, Wang et al [3] provide additional insight into this
problem. This group from Beijing performed a careful
metabolic balance study with a 3-day dietary record on
the intake and 24-hour dialysate and urine collection
on the dialysis removal of phosphate in 41 stable PD
patients. Over 50% of patients had serum phosphate
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levels above 1.8 mmol/L. Given the prolonged duration
on dialysis prior to the study, these patients probably
had minimal residual renal function. Not unexpectedly,
serum phosphate levels correlated closely with dietary
protein intake. However, the average dietary protein
intake was 0.8 g/kg/day, which is below the level
recommended by the Kidney and Dialysis Outcome
Quality Initiative [4] and that in the previously men-
tioned study from Hong Kong [2], while the dietary
phosphate intake was around 600 mg/day. In other
words, a low protein Chinese diet does not equal phos-
phate restriction. More interestingly, over 60% of the
hyperphosphatemic patients received calcium carbon-
ate as a phosphate binder in this study [3]. Positive cal-
cium balance was demonstrated in many of the patients,
and almost 20% had a certain degree of hypercalce-
mia together with hyperphosphatemia – an ominous
combination.
Serum phosphate level is strongly associated with
the mortality of hemodialysis patients and, probably,
PD patients. The mechanisms by which hyper-
phosphatemia contributes to increased mortality in
dialysis patients are not fully understood, but increased
cardiovascular calcification is the mechanism that is
most commonly suggested [5]. Cardiac calcification has
been shown in more than 60% of dialysis patients. It
occurs in the myocardium, conduction tissues, cardiac
valves, and coronary arteries, and is associated with
increased calcium phosphorus product. Patients with
serum phosphorus levels greater than 2.1 mmol/L had
a 52% greater relative risk for mortality from coronary
artery disease and a 26% greater relative risk for sudden
death compared with those who had serum phosphorus
levels of 0.8–2.1 mmol/L. Every 0.8 mmol2/L2 increase
in calcium phosphorus product was associated with an
11% increase in relative risk for mortality [5]. Another
recent study showed that cardiac valve calcification
predicted all-cause and cardiovascular mortality in PD
patients [6].
Given the important link between hyperphos-
phatemia, cardiovascular calcification, and the excess
in cardiovascular mortality and morbidity, better mea-
sures are needed for the control of hyperphosphate-
mia in dialysis patients. Sevelamer, vitamin D analogs
and calcimimetics are among the new agents in the
armamentarium of nephrologists in the battle against
hyperphosphatemia [7]. They are generally safe and
effective in suppressing parathyroid hormone and re-
ducing serum phosphate levels, especially in patients
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who have been resistant to conventional medical treat-
ment. Nevertheless, what we need is long-term study
on the efficacy of these agents in reducing cardio-
vascular diseases in dialysis patients.
Cheuk-Chun Szeto
Deputy Editor
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